TABLE 3.

Univariate and multivariate analyses of overall survival and disease-free survival.

	OS			DFS
	Univariate analysis	Multivariate analysis		Univariate analysis	Multivariate analysis
Variable	P	HR (95% CI)	P	P	HR (95% CI)	P
Age
<60
≥60	0.245	−	−	0.453	−	−
Gender
Female
Male	0.106	−	−	0.368	−	−
Smoking	0.126	−	−	0.103
Never
Ever
Differentiation
Good
Moderate
Poor	0.309	−	−	0.181	−	−
Histological cell type
Squamous cell carcinoma
Adenocarcinoma	0.249	−	−	0.062	−	−
pT stage
I
II
III	0.152	−	−	0.002∗	1.334 (0.958 to 1.859)	0.088
pTNM stage
I
II
III	< 0.001∗	2.421 (1.221 to 4.801)	0.011∗	< 0.001∗	2.055 (1.100 to 3.840)	0.024∗
Lymph node metastasis
Present
Absent	< 0.001∗	0.928 (0.561 to 1.534)	0.771	0.001∗	0.881(0.547 to1.419)	0.602
Adjuvant chemotherapy
No
Yes	0.003∗	0.982 (0.496 to 1.946)	0.959	0.018∗	1.154(0.657 to2.028)	0.618
Adjuvant radiotherapy
No
Yes	0.165	−	−	0.008∗	0.497(0.263 to 0.940)	0.032∗
SOD1 expression
Low	< 0.001∗	1.858 (1.164 to 2.966)	0.009∗	0.002∗	1.605 (1.056 to 2.440)	0.027∗
High

Abbreviations: NSCLC, non-small cell lung cancer; pTNM stage, tumor node metastasis (pathological stage); pT, pathological T stage; n, number of patients; OS, overall survival; DFS, disease-free survival; HR, hazard ratio; CI, confidence interval. pTNM stage, lymph node metastasis, and SOD1 expression were selected for inclusion in multivariate analysisfor OS. Histological cell type, pTNM stage, lymph node metastasis, and SOD1 expression were selected for inclusion in multivariate analysis for DFS. ^∗P < 0.05 was considered statistically significant.